Peter J Wild

List of Publications by Year
in descending order

170 papers	11,128 citations	34105 52 h-index	34986 98 g-index
185 all docs	185 docs citations	185 times ranked	19763 citing authors

#	ARTICLE	IF	CITATIONS
1	Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nature Methods, 2014, 11, 417-422.	19.0	1,430
2	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics, 2012, 44, 685-689.	21.4	1,300
3	Automated Gleason grading of prostate cancer tissue microarrays via deep learning. Scientific Reports, 2018, 8, 12054.	3.3	278
4	Prostate cancerâ€"associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine, 2017, 23, 1063-1071.	30.7	240
5	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, 402.	6.3	229
6	TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell, 2016, 29, 846-858.	16.8	228
7	Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science, 2014, 346, 85-89.	12.6	200
8	Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. Journal of Experimental Medicine, 2009, 206, 221-232.	8.5	193
9	Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology, 2010, 51, 1244-1254.	7.3	182
10	Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3342-3347.	7.1	175
11	Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-Aâ€"Induced Angiogenesis. Cancer Research, 2013, 73, 1097-1106.	0.9	150
12	Prediction of Progression of Nonâ€"Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. European Urology, 2008, 54, 835-844.	1.9	148
13	Molecular Profiling of Laser-Microdissected Matched Tumor and Normal Breast Tissue Identifies Karyopherin Î±2 as a Potential Novel Prognostic Marker in Breast Cancer. Clinical Cancer Research, 2006, 12, 3950-3960.	7.0	145
14	SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. Neoplasia, 2014, 16, 14-W10.	5.3	145
15	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nature Medicine, 2017, 23, 1046-1054.	30.7	145
16	HER3 Is a Determinant for Poor Prognosis in Melanoma. Clinical Cancer Research, 2008, 14, 5188-5197.	7.0	142
17	Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer, 2008, 8, 42.	2.6	139
18	MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy. Neoplasia, 2010, 12, 628-636.	5.3	131

#	Article	IF	Citations
19	Combined mutation of *Vhl* and *Trp53* causes renal cysts and tumours in mice. EMBO Molecular Medicine, 2013, 5, 949-964.	6.9	131
20	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	8.2	130
21	Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08). European Urology, 2013, 64, 150-158.	1.9	120
22	DNA Methylation Signatures for Prediction of Biochemical Recurrence After Radical Prostatectomy of Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 3250-3258.	1.6	117
23	FOXA1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castration-Resistant Prostate Cancer. American Journal of Pathology, 2012, 180, 848-861.	3.8	115
24	Reassessing the Current UICC/AJCC TNM Staging for Renal Cell Carcinoma. European Urology, 2009, 56, 636-643.	1.9	114
25	Profiling gastrinâ€releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates. Prostate, 2012, 72, 318-325.	2.3	111
26	Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology, 2009, 49, 1602-1609.	7.3	110
27	Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nature Medicine, 2017, 23, 869-877.	30.7	101
28	Highâ€throughput proteomic analysis of <scp>FFPE</scp> tissue samples facilitates tumor stratification. Molecular Oncology, 2019, 13, 2305-2328.	4.6	100
29	Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder. Clinical Cancer Research, 2005, 11, 4415-4429.	7.0	97
30	Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer. Clinical Cancer Research, 2010, 16, 88-98.	7.0	94
31	KPNA2 Expression Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research, 2011, 17, 1111-1121.	7.0	93
32	Hypermethylation of the *GABREâˆ¼miR-452âˆ¼miR-224* Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research, 2014, 20, 2169-2181.	7.0	86
33	FGFR3 Mutations and a Normal CK20 Staining Pattern Define Low-Grade Noninvasive Urothelial Bladder Tumours. European Urology, 2007, 52, 760-768.	1.9	84
34	Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer, 2009, 9, 217.	2.6	81
35	Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. Oncotarget, 2015, 6, 32748-32760.	1.8	81
36	Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (<scp>ERSPC</scp>) and Prostate Cancer Prevention Trial (<scp>PCPT</scp>) risk calculators: independent validation and comparison in a contemporary European cohort. BJU International, 2016, 117, 401-408.	2.5	76

#	Article	IF	Citations
37	Strategies to enable large-scale proteomics for reproducible research. Nature Communications, 2020, 11, 3793.	12.8	75
38	Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer, 2010, 10, 273.	2.6	74
39	TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Experimental and Molecular Pathology, 2013, 95, 235-241.	2.1	74
40	Nuclear karyopherin α2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. International Journal of Cancer, 2008, 123, 1433-1438.	5.1	70
41	Dosimetry and First Clinical Evaluation of the New ^{18}F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 372-378.	5.0	70
42	ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. European Urology, 2008, 54, 1097-1108.	1.9	69
43	A Seven-Marker Signature and Clinical Outcome in Malignant Melanoma: A Large-Scale Tissue-Microarray Study with Two Independent Patient Cohorts. PLoS ONE, 2012, 7, e38222.	2.5	67
44	Expression of Serotonin Receptors in Human Hepatocellular Cancer. Clinical Cancer Research, 2012, 18, 5902-5910.	7.0	66
45	Frequent expression of the novel cancer testis antigen MAGE‑C2/CT‑10 in hepatocellular carcinoma. International Journal of Cancer, 2009, 124, 352-357.	5.1	63
46	Neogenesis and maturation of transient Golgi-like cisternae in a simple eukaryote. Journal of Cell Science, 2009, 122, 2846-2856.	2.0	62
47	A versatile modular vector system for rapid combinatorial mammalian genetics. Journal of Clinical Investigation, 2015, 125, 1603-1619.	8.2	62
48	The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. Gut, 2008, 57, 243-251.	12.1	61
49	Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clinical Pathology, 2014, 14, 10.	1.8	61
50	Expression of the Lipid Transporters ABCA3 and ABCA1 is Diminished in Human Breast Cancer Tissue. Hormone and Metabolic Research, 2010, 42, 102-109.	1.5	60
51	p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Molecular Medicine, 2012, 4, 808-824.	6.9	60
52	Combined genetic and epigenetic alterations of the *TERT* promoter affect clinical and biological behavior of bladder cancer. International Journal of Cancer, 2019, 144, 1676-1684.	5.1	57
53	Nuclear detection of Y-boxprotein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer, 2009, 9, 410.	2.6	55
54	Down-Regulation of Methylthioadenosine Phosphorylase (MTAP) Induces Progression of Hepatocellular Carcinoma via Accumulation of 5′-Deoxy-5′-Methylthioadenosine (MTA). American Journal of Pathology, 2011, 178, 1145-1152.	3.8	54

#	Article	IF	Citations
55	The Application of Artificial Intelligence to Microarray Data: Identification of a Novel Gene Signature to Identify Bladder Cancer Progression. European Urology, 2010, 57, 398-406.	1.9	52
56	Reduced Expression of Fibroblast Growth Factor Receptor 2IIIb in Hepatocellular Carcinoma Induces a More Aggressive Growth. American Journal of Pathology, 2010, 176, 1433-1442.	3.8	52
57	Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines. IScience, 2019, 21, 664-680.	4.1	52
58	Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers. Life Science Alliance, 2018, 1, e201800042.	2.8	51
59	Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome. European Urology, 2011, 60, 1235-1243.	1.9	49
60	Biological Relevance and Therapeutic Potential of the Hypusine Modification System. Journal of Biological Chemistry, 2015, 290, 18343-18360.	3.4	48
61	AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer. Journal of Experimental Medicine, 2020, 217, .	8.5	48
62	Cytology smears as excellent starting material for next‐generation sequencing‐based molecular testing of patients with adenocarcinoma of the lung. Cancer Cytopathology, 2017, 125, 30-40.	2.4	47
63	MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer. PLoS ONE, 2011, 6, e21366.	2.5	47
64	Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma. Carcinogenesis, 2014, 35, 1407-1415.	2.8	46
65	The Bayesian group-Lasso for analyzing contingency tables. , 2009, , .		45
66	Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2009, 15, 3297-3304.	7.0	44
67	Fatal outcome after heart transplantation caused by <i><scp>A</scp>spergillus lentulus</i>. Transplant Infectious Disease, 2012, 14, E60-3.	1.7	44
68	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget, 2018, 9, 10284-10293.	1.8	44
69	Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer—what has gone wrong? A blueprint for the way forward in biomarker studies. British Journal of Cancer, 2015, 112, 140-148.	6.4	43
70	RNA expression profiling of normal and tumor cells following photodynamic therapy with 5-aminolevulinic acid—induced protoporphyrin IX in vitro. Molecular Cancer Therapeutics, 2005, 4, 516-528.	4.1	42
71	Nutritional depletion and its relationship to respiratory impairment in patients with chronic respiratory failure due to COPD or restrictive thoracic diseases. European Journal of Clinical Nutrition, 2008, 62, 436-443.	2.9	42
72	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. Molecular and Cellular Proteomics, 2019, 18, 1836-1850.	3.8	42

#	Article	IF	Citations
73	Exploring the Nuclear Envelope of Herpes Simplex Virus 1-Infected Cells by High-Resolution Microscopy. Journal of Virology, 2009, 83, 408-419.	3.4	41
74	Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Research, 2010, 2010, 1-11.	2.4	41
75	Formation of Renal Cysts and Tumors in <i>Vhl/Trp53</i>-Deficient Mice Requires HIF1Î± and HIF2Î±. Cancer Research, 2016, 76, 2025-2036.	0.9	40
76	Detection of Urothelial Bladder Cancer Cells in Voided Urine Can Be Improved by a Combination of Cytology and Standardized Microsatellite Analysis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1798-1806.	2.5	38
77	Identification of new genes associated with melanoma. Experimental Dermatology, 2011, 20, 502-507.	2.9	37
78	Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center. European Urology Focus, 2021, 7, 95-101.	3.1	37
79	Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. Experimental Dermatology, 2010, 19, e251-7.	2.9	35
80	Increased expression of transcription factor TFAP2Î± correlates with chemosensitivity in advanced bladder cancer. BMC Cancer, 2011, 11, 135.	2.6	35
81	Comparative analysis of mRNA and protein degradation in prostate tissues indicates high stability of proteins. Nature Communications, 2019, 10, 2524.	12.8	35
82	Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. Journal of Clinical Pathology, 2015, 68, 819-824.	2.0	34
83	Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. Prostate, 2017, 77, 549-556.	2.3	34
84	AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations. Modern Pathology, 2010, 23, 177-186.	5.5	33
85	Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features. European Radiology, 2020, 30, 6757-6769.	4.5	33
86	Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q. Human Pathology, 2008, 39, 1621-1629.	2.0	31
87	The Androgen-Regulated Calcium-Activated Nucleotidase 1 (CANT1) Is Commonly Overexpressed in Prostate Cancer and Is Tumor-Biologically Relevant in Vitro. American Journal of Pathology, 2011, 178, 1847-1860.	3.8	31
88	Low Frequency of Epigenetic Events in Urothelial Tumors in Young Patients. Journal of Urology, 2010, 184, 459-463.	0.4	28
89	Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. Scientific Reports, 2016, 6, 24146.	3.3	28
90	Detecting circulating tumor DNA in renal cancer: An open challenge. Experimental and Molecular Pathology, 2017, 102, 255-261.	2.1	28

#	Article	IF	Citations
91	KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics. Journal of Molecular Diagnostics, 2013, 15, 299-311.	2.8	27
92	CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. Journal of Clinical Investigation, 2020, 130, 2435-2450.	8.2	27
93	Genetic and Epigenetic *SLC18A2* Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research, 2009, 15, 1400-1410.	7.0	26
94	Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 437-443.	2.8	26
95	Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 623-631.	2.8	26
96	Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants. JAMA Surgery, 2019, 154, e190484.	4.3	26
97	Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. Histopathology, 2008, 52, 674-681.	2.9	25
98	Expression of the Endothelin Axis in Noninvasive and Superficially Invasive Bladder Cancer: Relation to Clinicopathologic and Molecular Prognostic Parameters. European Urology, 2009, 56, 837-847.	1.9	23
99	Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. International Journal of Cancer, 2012, 130, 885-895.	5.1	23
100	KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. Journal of Pathology, 2014, 234, 239-252.	4.5	23
101	Combined deletion of *Vhl*, *Trp53* and *Kif3a* causes cystic and neoplastic renal lesions. Journal of Pathology, 2016, 239, 365-373.	4.5	23
102	Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 419-427.	2.8	22
103	RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Oncotarget, 2017, 8, 5774-5788.	1.8	22
104	Downregulation of SPTAN1 is related to MLH1 deficiency and metastasis in colorectal cancer. PLoS ONE, 2019, 14, e0213411.	2.5	22
105	A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients. Scientific Data, 2017, 4, 170014.	5.3	21
106	Alterations in *BAP1* Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. Clinical Cancer Research, 2021, 27, 2277-2291.	7.0	21
107	Impact of rescanning and repositioning on radiomic features employing a multi-object phantom in magnetic resonance imaging. Scientific Reports, 2021, 11, 14248.	3.3	21
108	No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. International Journal of Cancer, 2009, 125, 2205-2208.	5.1	20

#	Article	IF	Citations
109	Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Formation. Journal of the American Society of Nephrology: JASN, 2015, 26, 2778-2788.	6.1	20
110	Large‐scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. Molecular Oncology, 2016, 10, 825-837.	4.6	20
111	Evidence of renal angiomyolipoma neoplastic stem cells arising from renal epithelial cells. Nature Communications, 2017, 8, 1466.	12.8	20
112	Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. International Journal of Molecular Sciences, 2017, 18, 2017.	4.1	20
113	Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Frontiers in Oncology, 2020, 10, 1299.	2.8	20
114	Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma. International Journal of Cancer, 2013, 133, n/a-n/a.	5.1	19
115	Retroperitoneal teratoma with somatic malignant transformation: A papillary renal cell carcinoma in a testicular germ cell tumour metastasis following platinum-based chemotherapy. BMC Urology, 2013, 13, 9.	1.4	18
116	Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. Journal of Cancer, 2017, 8, 323-331.	2.5	18
117	Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair. Oncogene, 2019, 38, 3616-3635.	5.9	17
118	Convergent network effects along the axis of gene expression during prostate cancer progression. Genome Biology, 2020, 21, 302.	8.8	17
119	Tissue Microarray Analysis of Methylthioadenosine Phosphorylase Protein Expression in Melanocytic Skin Tumors. Archives of Dermatology, 2006, 142, 471-6.	1.4	16
120	Intrafascial Dissection Significantly Increases Positive Surgical Margin and Biochemical Recurrence Rates after Robotic-Assisted Radical Prostatectomy. Urologia Internationalis, 2012, 89, 17-24.	1.3	16
121	Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer. World Journal of Urology, 2019, 37, 1837-1844.	2.2	16
122	Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer. Oncotarget, 2017, 8, 14794-14805.	1.8	16
123	A potential predictive marker for response to interferon in malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2007, 5, 456-459.	0.8	15
124	Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic Hyperplasia. Journal of Virology, 2012, 86, 8461-8471.	3.4	15
125	Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression. Frontiers in Oncology, 2018, 8, 40.	2.8	15
126	Diagnostic Accuracy of a MR Protocol Acquired with and without Endorectal Coil for Detection of Prostate Cancer: A Multicenter Study. Current Urology, 2019, 12, 88-96.	0.6	15

#	Article	IF	Citations
127	Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. Blood Advances, 2020, 4, 2477-2488.	5.2	15
128	Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. Oncotarget, 2017, 8, 31765-31774.	1.8	15
129	Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. Carcinogenesis, 2012, 33, 781-790.	2.8	13
130	Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncology Letters, 2015, 10, 2753-2760.	1.8	13
131	Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing â€" a case report. BMC Cancer, 2017, 17, 66.	2.6	13
132	Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis. Scientific Reports, 2018, 8, 3477.	3.3	13
133	Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinomaâ€"a single center retrospective study. Pathology Research and Practice, 2018, 214, 572-578.	2.3	13
134	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 603.e1-603.e7.	1.6	13
135	Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. Diagnostics, 2021, 11, 882.	2.6	13
136	Deep learning based on hematoxylinâ€"eosin staining outperforms immunohistochemistry in predicting molecular subtypes of gastric adenocarcinoma. Journal of Pathology, 2022, 257, 218-226.	4.5	13
137	High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. International Journal of Oncology, 2005, 27, 385-91.	3.3	13
138	Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. Pathology Research and Practice, 2018, 214, 957-963.	2.3	11
139	Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	11
140	Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. Journal of Pathology Informatics, 2016, 7, 3.	1.7	10
141	Weakly Supervised Cell Nuclei Detection and Segmentation on Tissue Microarrays of Renal Clear Cell Carcinoma. Lecture Notes in Computer Science, 2008, , 173-182.	1.3	9
142	A novel germline mutation of PDGFR-Î² might be associated with clinical response of colorectal cancer to regorafenib. Annals of Oncology, 2015, 26, 246-248.	1.2	8
143	Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling. American Journal of Pathology, 2020, 190, 1960-1970.	3.8	8
144	In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 423-432.	2.8	7

#	Article	IF	Citations
145	Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. Cell Reports Medicine, 2022, 3, 100604.	6.5	7
146	Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial. Breast Cancer Research and Treatment, 2011, 126, 643-651.	2.5	6
147	Clinical impact of prostate biopsy undergrading in an academic and community setting. World Journal of Urology, 2016, 34, 1481-1490.	2.2	6
148	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry â€" Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. Journal of Thoracic Oncology, 2018, 13, 1851-1863.	1.1	6
149	Mouse genetic background influences whether <i>HrasG12V</i> expression plus <i>Cdkn2a</i> knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. Oncotarget, 2018, 9, 19753-19766.	1.8	6
150	Infinite mixture-of-experts model for sparse survival regression with application to breast cancer. BMC Bioinformatics, 2010, 11, S8.	2.6	5
151	Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. Experimental Hematology and Oncology, 2014, 3, 18.	5.0	5
152	Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features. Journal of Cancer Research and Clinical Oncology, 2018, 144, 865-874.	2.5	5
153	Inferring clonal composition from multiple tumor biopsies. Npj Systems Biology and Applications, 2020, 6, 27.	3.0	5
154	Impact of â€œTime-From-Biopsy-to-Prostatectomyâ€•on Adverse Oncological Results in Patients With Intermediate and High-Risk Prostate Cancer. Frontiers in Surgery, 2020, 7, 561853.	1.4	5
155	Randomized Tree Ensembles for Object Detection in Computational Pathology. Lecture Notes in Computer Science, 2009, , 367-378.	1.3	5
156	A novel 5x multiplex immunohistochemical staining reveals PSMA as a helpful marker in prostate cancer with low p504s expression.. Pathology Research and Practice, 2021, 228, 153667.	2.3	5
157	Tumor-associated immune cell infiltrate density in penile squamous cell carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1159-1169.	2.8	5
158	Influence of Varying Assessment Parameters on the Diagnostic Accuracy of Magnetic Resonance Imaging in the Local Staging of Prostate Cancer. Urologia Internationalis, 2016, 96, 309-314.	1.3	4
159	Novel RGAG1-BCOR gene fusion revealed in a somatic soft tissue sarcoma with a long follow-up. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1107-1114.	2.8	4
160	Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial. Frontiers in Oncology, 2022, 12, 817692.	2.8	4
161	Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma. PLoS ONE, 2017, 12, e0186102.	2.5	3
162	Prevalence and causes of abnormal PSA recovery. Clinical Chemistry and Laboratory Medicine, 2018, 56, 341-349.	2.3	3

#	Article	IF	Citations
163	Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers, 2021, 13, 1852.	3.7	3
164	Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer. Clinical Proteomics, 2022, 19, 9.	2.1	3
165	Laser Microdissection for Microsatellite Analysis in Colon and Breast Cancer. , 2005, 293, 93-102.		2
166	BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 510-518.	1.6	2
167	Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy. Journal of Clinical Medicine, 2022, 11, 2057.	2.4	1
168	Serine threonine kinase 15 amplification in normal urothelium of cystectomy specimens is no prognostic factor in urothelial carcinoma of the bladder. Pathology Research and Practice, 2011, 207, 161-163.	2.3	0
169	Computational Pathology. , 2017, , 263-279.		0
170	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. Journal of Molecular Diagnostics, 2022, , .	2.8	0